查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929548

化学品CDMO市场：按服务、营运规模、药物模式、治疗领域、技术和最终用途分類的全球预测，2026-2032年

Chemical Drug CDMO Market by Service Type, Operational Scale, Drug Modality, Therapeutic Area, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，化学和製药 CDMO 市场价值将达到 65.5 亿美元，到 2026 年将成长到 70.1 亿美元，到 2032 年将达到 101.2 亿美元，年复合成长率为 6.41%。

关键市场统计数据
基准年 2025 65.5亿美元
预计年份：2026年 70.1亿美元
预测年份 2032 101.2亿美元
复合年增长率 (%) 6.41%

权威概述了不断变化的客户需求、治疗模式的复杂性以及正在重塑您的化学製药合约开发和生产策略的营运能力。

化学和製药CDMO产业正处于战略转折点，科学的复杂性、日益严格的监管以及商业性需求交织在一起，重塑整个製药产品和原料药价值链中的企业决策。本导言重点阐述了影响外包选择的核心趋势，包括对口服、注射和外用药物开发一体化服务日益增长的需求，以及大小分子原料原料药生产不同的技术要求。它还着重介绍了申办方如何围绕内部研发和经济高效的研发路径重新调整其产品组合，从而推动了对能够将产品从临床前阶段无缝过渡到临床和商业化规模生产的合作伙伴的需求。

技术创新、日益严格的监管以及对端到端服务的期望将如何推动化学和製药CDMO生态系统的策略演进

在技​​术创新、法规演变和赞助商策略调整的推动下，生物製药产业正经历变革性的变化，这对合约研发生产机构（CDMO）的各项服务提出了新的要求。生物製程技术和聚合物分析技术的进步、精密的化学合成以及流动化学的应用，共同提高了技术准入门槛，并实现了更快、更可重复的生产途径。这种技术发展势头促使供应商拓展其能力范围，涵盖小分子合成和生物製药生产，从而促进能够支持混合开发项目的一体化服务模式的形成。

2025年关税政策变化对医药化学品製造业全球筹资策略、区域产能决策与伙伴关係模式的影响

2025年美国关税的累积影响为管理全球分散供应链的赞助商和契约製造带来了新的营运和策略考量。虽然关税的影响因製剂形式和原材料而异，但其存在迫使企业重新评估筹资策略，优先考虑区域製造地，并加快关键中间体和成品生产能力的本地化。这种重新评估在小分子化学合成途径中尤其显着，因为这些途径的原料和中间体成本对进口关税非常敏感；在註射剂和外用製剂中也同样如此，因为这些製剂的包装和无菌组件的供应链受到严格控制。

关键細項分析突显了技术能力、治疗重点和营运规模的交集，为 CDMO（合约契约製造组织）释放了高价值的机会。

详细的市场区隔分析突显了需求成长领域和产能缺口，为有针对性的投资和商业性重点提供了切实可行的蓝图。以服务类型划分，清楚展现了药物製剂和原料药的发展轨迹。在药物製剂领域，口服、注射和外用剂型各自具有独特的监管和生产特点，这些特点会影响临床试验所需时间和规模化生产的复杂性。同时，原料药细分也明确区分了大分子生物製药和小分子化学品的生产需求及其不同的製程开发要求。依企业规模划分，凸显了能够将临床前活动、临床试验（I期、II期、III期）和商业化营运衔接起来的供应商的重要性，这反映了申办方对连续性和降低技术转移风险的期望。

全球市场的区域趋势和监管因素正在影响产能优先事项、客户参与模式和技术投资选择。

区域趋势正以不同的方式影响全球营运中产能扩张、客户互动和监管准备的策略重点。在美洲，强劲的研发管线推动了生物技术公司和成熟製药公司的需求，他们专注于快速推进临床试验以及从研发到商业化的一体化路径。区域监管协调和供应商生态系统为投资商业规模能力和先进分析技术提供了支援。在欧洲、中东和非洲地区，复杂的法规结构和专业中心接近性有利于那些拥有专业人才库和深厚临床网路的提案商。

策略能力投资、平台专业化和整合服务模式使顶级契约製造脱颖而出，并影响其合作伙伴的选择。

化学製药CDMO生态系统中的主要企业凭藉技术专长、地域覆盖和服务整合能力脱颖而出，从而赢得复杂的研发项目和长期商业合约。为了满足新型生物疗法的严格要求，一些供应商正大力投资生技药品平台和大分子製程开发，拓展分析特性、细胞培养放大和低温运输物流能力。另一些供应商则将资金集中于模组化化学合成设施和流动化学技术，以实现小分子原料药和中间体的快速放大和更精准的製程控制。

经营团队的策略包括投资产能扩张、营运柔软性和伙伴关係模式，以确保强劲成长和市场领导地位。

产业领导者应采取多管齐下的策略议程，在管理投资组合风险的同时，抓住新的机会。优先投资以弥补能力差距，例如扩大生物製剂加工能力、实施流动化学技术以及加强分析和数位化品质框架，对于赢得需要深厚技术实力的专案至关重要。同时，建构涵盖临床前到商业化规模生产的灵活营运能力，可以减少技术转移过程中的摩擦，并最大限度地降低拥有多阶段研发管线的申办者的供应中断风险。为因应贸易政策波动，企业还应制定正式的策略采购和供应商风险缓解计划，其中包括替代原料来源和地理冗余。

一个稳健的多方法研究框架，结合了关键相关人员访谈、二手证据检验验证和能力映射，以确保研究结果可操作且检验。

本研究整合了定性专家访谈、与关键相关人员的面对面交流以及多来源的二手数据，旨在全面客观地呈现化学和製药CDMO行业的概况。主要资讯来源包括对赞助机构的高级研发和供应链主管、生产基地的技术和营运主管以及法规事务专家的结构化访谈，从而深入观点能力需求、风险因素和决策驱动因素。二手检验整合了已发布的监管指南、专利和科学文献、行业会议纪要以及公司资讯披露，所有数据均经过三角验证，以确保事实准确性和背景相关性。

对产业转型、关键能力和策略选择进行权威的综合分析，这些分析将决定CDMO在各个治疗领域和地区的竞争力。

总之，化学和製药CDMO产业正经历着深刻的变革时期，技术、​​法规和客户期望相互交织，重新定义了竞争优势。赞助商越来越倾向于寻找能够帮助他们从早期研发、临床试验到商业化规模生产的无缝衔接的合作伙伴，涵盖小分子和大分子药物。关税趋势和不断变化的区域政策正在加速策略采购决策，并推动对区域产能建设和供应链冗余的投资，凸显了灵活且具韧性的营运模式的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依服务类型分類的化学品CDMO市场

  • 药物製剂
    • 口服
    • 注射
    • 外用药物
  • 原料药
    • 聚合物化合物
    • 低分子

第九章 依企业规模分類的化学品CDMO市场

  • 商业规模
  • 临床前/临床阶段
    • I期试验
    • 二期/三期
    • 临床前阶段

10. 依药物剂型分類的化学药物CDMO市场

  • 聚合物化合物
  • 低分子

第十一章 依治疗领域分類的化学品CDMO市场

  • 循环系统
  • 神经病学
  • 肿瘤学

12. 按技术分類的化学品CDMO市场

  • 生物
  • 化学合成
  • 流动化学

第十三章 依最终用户分類的化学品CDMO市场

  • 生技公司
  • 学名药生产商
  • 製药公司

第十四章 各地区化学品CDMO市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 化学品CDMO市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国化学品CDMO市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国化学品CDMO市场

第十八章：中国化工CDMO市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Almac Group Limited
  • AMRI
  • Aurobindo Pharma USA Inc.
  • BASF SE
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cambrex Charles City LLC
  • Catalent, Inc.
  • Curia Global, Inc.
  • Dawson Pharma Services Ltd.
  • DPT Laboratories LLC
  • Eurofins Scientific SE
  • Evonik Industries AG
  • Hovione LLC
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • PCI Synthesis
  • Piramal Enterprises Limited
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Synthon BV
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-0A380695180F

The Chemical Drug CDMO Market was valued at USD 6.55 billion in 2025 and is projected to grow to USD 7.01 billion in 2026, with a CAGR of 6.41%, reaching USD 10.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.55 billion
Estimated Year [2026] USD 7.01 billion
Forecast Year [2032] USD 10.12 billion
CAGR (%) 6.41%

An authoritative overview of evolving client demands, modality complexity, and operational capabilities reshaping chemical drug contract development and manufacturing strategies

The chemical drug CDMO landscape is at a strategic inflection point where scientific complexity, regulatory rigor, and commercial imperatives converge to reshape enterprise decision-making across drug product and drug substance value chains. This introduction frames the core dynamics influencing outsourcing choices, including the escalating need for integrated services that span oral, parenteral, and topical drug product development as well as the differentiated technical demands of large molecule and small molecule drug substance manufacturing. It underscores how sponsors are rebalancing portfolios between proprietary innovation and cost-effective development pathways, driving demand for partners who can seamlessly transition assets from preclinical stages through clinical phases and into commercial-scale production.

Moreover, the narrative highlights the growing interplay between modality-specific capabilities and specialized technologies, from biological processing to advanced chemical synthesis and flow chemistry, which are informing strategic partnerships. The introduction also situates end-user motivations-biotech companies prioritizing speed to clinic, generic companies focusing on cost optimization, and pharmaceutical companies seeking supply chain resilience-within a broader context of regulatory scrutiny and patient-centric expectations. Taken together, these elements set the stage for understanding how CDMOs must evolve their operational models, invest in targeted capabilities, and align commercial offerings to meet increasingly differentiated client requirements while maintaining compliance and scalability

How technological advances, regulatory tightening, and end-to-end service expectations are catalyzing strategic evolution across the chemical drug CDMO ecosystem

The industry is undergoing transformative shifts driven by technological innovation, regulatory evolution, and strategic realignment of sponsor priorities, producing new imperatives for CDMOs across service portfolios. Advances in biological processing and large molecule analytics, coupled with enhanced chemical synthesis techniques and the adoption of flow chemistry, are elevating technical entry barriers and enabling faster, more reproducible manufacturing routes. This technological momentum is pushing providers to expand their capability sets to include both small molecule syntheses and biologics manufacturing, thereby fostering integrated service models that can accommodate hybrid development programs.

Simultaneously, operational scale considerations are changing the calculus for investment and client engagement; firms that can support the full continuum from preclinical through Phase I, II, and III to commercial-scale production are increasingly favored by sponsors seeking continuity and risk mitigation. Regulatory agencies are intensifying expectations for process control, supply chain traceability, and quality by design approaches, which in turn encourages CDMOs to embed advanced analytics and digital quality systems into their operations. This confluence of scientific advancement, regulatory sophistication, and customer-driven demand for end-to-end solutions is redefining competitive differentiation and accelerating consolidation among providers that can demonstrate both technical depth and operational scale

How 2025 tariff policy changes are reshaping global sourcing strategies, regional capacity decisions, and partnership models across chemical drug manufacturing

The cumulative impact of the United States tariff measures enacted in 2025 has introduced new operational and strategic considerations for sponsors and contract manufacturers that manage globally distributed supply chains. While tariffs have varied effects across modalities and materials, their presence has prompted companies to reassess sourcing strategies, prioritize regional manufacturing footprints, and accelerate localization of critical intermediates and finished product capabilities. This recalibration has had particular resonance for small molecule chemical synthesis pathways where feedstock and intermediate costs are sensitive to import duties, and for parenteral and topical drug products that rely on tightly controlled supply chains for packaging and sterile components.

In response, many organizations have increased investments in dual-sourcing strategies, secured alternative supplier relationships outside affected corridors, and pursued reshoring where regulatory and economic conditions support onshore capacity expansion. The tariffs have also emphasized the value of flexible manufacturing platforms and modular technologies that can be redeployed across regions to mitigate cost exposure. Moreover, strategic procurement teams are leveraging longer-term supply agreements and collaborative risk-sharing arrangements with CDMO partners to preserve continuity while managing margin pressure. These adjustments collectively illustrate how trade policy shifts can accelerate structural changes in sourcing, capacity planning, and partnership models across the CDMO ecosystem

Critical segmentation intelligence revealing where technical capabilities, therapeutic focus, and operational scale converge to unlock high-value opportunities for CDMOs

A nuanced segmentation lens reveals where demand is intensifying and where capability gaps persist, offering a practical roadmap for targeted investment and commercial focus. Analyzing service type segmentation shows distinct trajectories for drug product and drug substance offerings; within drug product, oral, parenteral, and topical formats each have unique regulatory and manufacturing profiles that affect time to clinic and scale-up complexity, while drug substance segmentation separates the manufacturing needs of large molecule biologics from small molecule chemical entities and their divergent process development requirements. Operational scale segmentation underscores the premium placed on providers that bridge preclinical activity and the clinical phases-Phase I, Phase II, Phase III-through to commercial operations, reflecting sponsor preferences for continuity and reduced tech-transfer risk.

Drug modality segmentation confirms that capabilities for both large molecule and small molecule programs remain essential, yet they demand different capital equipment, analytics, and quality frameworks. End user segmentation differentiates the priorities of biotech companies seeking speed and flexibility, generic companies focused on cost efficiencies and regulatory know-how, and pharmaceutical firms that emphasize supply chain security and integrated lifecycle support. Therapeutic area segmentation highlights specialized needs in cardiovascular, neurology, and oncology programs where clinical demand, formulation complexity, and regulatory pathways diverge. Technology segmentation points to opportunities in biological platforms, conventional chemical synthesis, and the growing adoption of flow chemistry as a tool for process intensification and greater control. Taken together, these segmentation perspectives inform a targeted go-to-market approach and capability roadmap for providers aiming to capture high-value opportunities

Regional dynamics and regulatory factors that determine capacity priorities, client engagement models, and technology investment choices across global markets

Regional dynamics are shaping strategic priorities for capacity expansion, client engagement, and regulatory readiness in distinct ways across the global footprint. In the Americas, demand drivers include a strong pipeline environment in both biotech and established pharmaceutical firms, with an emphasis on speed to clinic and integrated development-to-commercial pathways; regional regulatory alignment and supplier ecosystems support investments in commercial-scale capabilities and advanced analytics. The Europe, Middle East & Africa region presents a complex mosaic of regulatory frameworks and center-of-excellence hubs, where proximity to specialized talent pools and deep clinical networks can favor providers that offer niche therapeutic expertise and complex formulation services.

Asia-Pacific continues to be a growth engine for manufacturing capacity, offering a blend of cost-competitive chemical synthesis capabilities and expanding biologics expertise, while policy shifts and trade measures are encouraging selective nearshoring within the region. Across regions, suppliers that can demonstrate compliance with local regulatory expectations, secure multi-regional supply continuity, and deliver technology transfer with minimal disruption are increasingly preferred. These regional insights should inform where to prioritize capital projects, how to structure client engagement models, and which local partnerships are essential to support customers operating across multiple regulatory jurisdictions

How strategic capability investments, platform specialization, and integrated service models are differentiating top contract manufacturers and influencing partner selection

Leading companies within the chemical drug CDMO ecosystem are differentiating through a combination of technical specialization, geographic footprint, and service integration, positioning themselves to capture complex development programs and long-term commercial contracts. Some providers are investing heavily in biologics platforms and large-molecule process development, expanding their capabilities in analytical characterization, cell-culture scale-up, and cold-chain logistics to meet the exacting demands of novel biologic therapeutics. Others are focusing their capital on modular chemical synthesis facilities and flow chemistry implementations that allow rapid scale transitions and greater process control for small molecule APIs and intermediates.

Strategic M&A and partnerships remain common routes to accelerate capability expansion, fill therapeutic area gaps, and create multi-modal service offerings. Companies that demonstrate robust quality systems, transparent regulatory track records, and scalable digital quality and manufacturing execution systems are more successful in securing enterprise-level, long-duration contracts. Additionally, providers that offer value-added services-such as integrated formulation development, clinical supply logistics, and regulatory support-are increasingly viewed as strategic partners rather than transactional suppliers. For clients, the vendor selection process now emphasizes a provider's ability to manage complex tech transfers, demonstrate consistency across sites, and provide adaptive capacity that aligns with evolving development timelines

Actionable strategies for executives to invest in capability expansion, operational flexibility, and partnership models that secure resilient growth and market leadership

Industry leaders should adopt a multi-pronged strategic agenda to capture emerging opportunities while managing risk across their portfolios. Prioritizing investments that close capability gaps-such as expanding biologics processing, adopting flow chemistry, and enhancing analytical and digital quality frameworks-will be crucial to winning programs that require technical depth. Simultaneously, building flexible operational footprints that can support preclinical through commercial-scale production reduces friction during tech transfers and minimizes supply disruptions for sponsors with multi-phase pipelines. Leaders should also formalize strategic sourcing and supplier-risk mitigation programs that incorporate alternative feedstock sources and regional redundancy to respond to trade-policy volatility.

Commercial strategies should emphasize integrated value propositions that combine development expertise, regulatory support, and supply chain continuity, thereby shifting client relationships from transactional engagements to long-term strategic partnerships. Investing in transparent compliance records, publishable case studies, and modular service offerings can accelerate client trust and shorten sales cycles. Finally, executives should explore targeted partnerships and selective M&A to accelerate capability acquisition, while maintaining disciplined integration playbooks to preserve quality and operational resilience. These combined actions will enable market leaders to capture high-value programs, maintain margin integrity, and position their organizations for sustainable growth

A robust multi-method research framework combining primary stakeholder interviews, secondary evidence triangulation, and capability mapping to ensure actionable and verifiable insights

This research synthesizes qualitative expert interviews, primary stakeholder engagements, and multi-source secondary data to produce a comprehensive, objective view of the chemical drug CDMO landscape. Primary inputs include structured interviews with senior R&D and supply chain leaders at sponsor organizations, operations and technical leads within manufacturing sites, and regulatory affairs specialists, providing real-world perspectives on capability requirements, risk factors, and decision drivers. Secondary research incorporates publicly available regulatory guidance, patent and scientific literature, industry conference proceedings, and company disclosures, all triangulated to ensure factual accuracy and contextual relevance.

Analytical methods involve capability mapping, comparative readiness assessments across service types and operational scales, and scenario analysis to understand the implications of trade policy shifts and technology adoption. The methodology also applies a rigorous quality assurance process that checks data integrity, corroborates interview findings with documented evidence, and validates conclusions through cross-functional analyst review. Where applicable, the research tests assumptions through sensitivity analysis and documents limitations and data exclusions to provide transparent context for users. This multi-method approach ensures that conclusions are grounded in practitioner experience and verifiable sources, offering stakeholders a reliable basis for strategic decisions

Final synthesis of sector-wide transformation, capability imperatives, and strategic choices that will determine CDMO competitiveness across therapeutic areas and regions

In conclusion, the chemical drug CDMO sector is navigating a period of substantive transformation where technology, regulation, and client expectations intersect to redefine competitive advantage. Sponsors increasingly demand partners that can provide seamless transitions from early development through clinical phases and into commercial-scale manufacturing, spanning both small molecule and large molecule modalities. Tariff developments and regional policy shifts have accelerated strategic sourcing decisions and prompted investments in regional capabilities and supply redundancy, underscoring the need for flexible, resilient operational models.

Providers that successfully integrate advanced technologies-ranging from biological platforms and enhanced analytics to flow chemistry and modular chemical synthesis-while maintaining rigorous quality and regulatory compliance will be best positioned to capture complex, high-value engagements. Strategic investments, targeted partnerships, and disciplined operational expansion will enable firms to meet the differentiated needs of biotech, generic, and pharmaceutical end users across cardiovascular, neurology, and oncology therapeutic areas. The landscape rewards those who combine technical excellence with commercial agility and a commitment to transparent, reliable delivery

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemical Drug CDMO Market, by Service Type

  • 8.1. Drug Product
    • 8.1.1. Oral
    • 8.1.2. Parenteral
    • 8.1.3. Topical
  • 8.2. Drug Substance
    • 8.2.1. Large Molecule
    • 8.2.2. Small Molecule

9. Chemical Drug CDMO Market, by Operational Scale

  • 9.1. Commercial Scale
  • 9.2. Preclinical Clinical Scale
    • 9.2.1. Phase I
    • 9.2.2. Phase II Iii
    • 9.2.3. Preclinical

10. Chemical Drug CDMO Market, by Drug Modality

  • 10.1. Large Molecule
  • 10.2. Small Molecule

11. Chemical Drug CDMO Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. Neurology
  • 11.3. Oncology

12. Chemical Drug CDMO Market, by Technology

  • 12.1. Biological
  • 12.2. Chemical Synthesis
  • 12.3. Flow Chemistry

13. Chemical Drug CDMO Market, by End User

  • 13.1. Biotech Companies
  • 13.2. Generic Companies
  • 13.3. Pharmaceutical Companies

14. Chemical Drug CDMO Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Chemical Drug CDMO Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Chemical Drug CDMO Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Chemical Drug CDMO Market

18. China Chemical Drug CDMO Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Almac Group Limited
  • 19.6. AMRI
  • 19.7. Aurobindo Pharma USA Inc.
  • 19.8. BASF SE
  • 19.9. Boehringer Ingelheim Pharma GmbH & Co. KG
  • 19.10. Cambrex Charles City LLC
  • 19.11. Catalent, Inc.
  • 19.12. Curia Global, Inc.
  • 19.13. Dawson Pharma Services Ltd.
  • 19.14. DPT Laboratories LLC
  • 19.15. Eurofins Scientific SE
  • 19.16. Evonik Industries AG
  • 19.17. Hovione LLC
  • 19.18. Jubilant Life Sciences Limited
  • 19.19. Lonza Group AG
  • 19.20. PCI Synthesis
  • 19.21. Piramal Enterprises Limited
  • 19.22. Recipharm AB
  • 19.23. Samsung Biologics Co., Ltd.
  • 19.24. Siegfried Holding AG
  • 19.25. Synthon BV
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMICAL DRUG CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHEMICAL DRUG CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE II III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE II III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHASE II III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY FLOW CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY FLOW CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY FLOW CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY GENERIC COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY GENERIC COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY GENERIC COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CHEMICAL DRUG CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CHEMICAL DRUG CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG SUBSTANCE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY OPERATIONAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY PRECLINICAL CLINICAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CHEMICAL DRUG CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)